

DAFTAR PUSTAKA

- Ahmadi R., Stockhammer F., Becker N., Hohlen, K., Misch M., Christian A., Dictus C., Herold-Mende C., Capper D., Untenberga A., Von Deimling A., Wick W, Hartmann C. 2012. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. *J Neurooncol*; 109, 15-22
- Alentorn A., Duran-Peña A., Pingle S.C., Piccioni D.E., Idbaih A., Kesari S. 2015. Molecular profiling of gliomas: potential therapeutic implications. *Expert Review. Anticancer Therapy*; 15: 955–962.
- Alifieris C., Trafalis D.T. 2015. Glioblastoma multiforme: Pathogenesis and Treatment. *Pharmacol. Therapy*; 152: 63–82.
- Arita H., Narita Y., Matsushita Y., Fukushima S., Yoshida A., Takami H., Miyakita Y., Ohno M., Shibui S., Ichimura K. 2015. Development of A Robust and Sensitive Pyrosequencing Assay for the Detection of IDH1/2 Mutations in Gliomas. *Brain Tumor Pathology*; 32, 22-30.
- Azcoitia., Santos-Galindo M., Arevalo M., Garcia-Segura L. 2010. Role of astroglia in the neuroplastic and neuroprotective actions of estradiol. *Eur J Neurosci* 32:1995-2002.
- Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., Von Deimling A. 2008. Analysis of the IDH1 Codon 132 Mutation in Brain Tumors. *Acta Neuropathology*; 116, 597-602.
- Barone., Gorski J., Greenberg S., Plunkett R. 2009. Estrogen increases survival in an orthotopic model of glioblastoma. *J Neurooncol* 95:37-48.
- Bermejo-Alvarez., Rizos D., Lonergan P., Gutierrez-Adan A. 2011. Transcriptional sexual dimorphism during preimplantation embryo development and its consequences for developmental competence and adult health and disease. *Reproduction* 141:563-570.
- Bleeker F. E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vdanertop W.P., Fratini M., Molinari F., Knowles M., Cerrato A., Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S., Marchetti A.& Bardelli A. 2009. IDH1 Mutations at Residue p.R132 (IDH1(R132)) Occur Frequently in High Grade Gliomas but Not in Other Solid Tumors. *Hum Mutant*; 30, 7-11.
- Boffetta P., Hashibe M. 2006. Alcohol and cancer. *Lancet Oncol*; 7(2):149–56.
- Bomford C., Kunkler I., Walter. 2003. Textbook of Radiotherapy Radiation Physics, Therapy dan Oncology. 6 edition. London: Churchill Livingstone
- Burger P., Scheithauer B., Paulus W. 2000. Pilocytic astrocytoma. Eds. Pathology dan Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 45-51.



- Braganza., Rajaraman., Park., Inskip., Freedman., Hollenbeck., Berrington de Gonza., Kitahara. 2014. Cigarette smoking, alcohol intake, and risk of glioma in the NIH-AARP Diet and Health Study. *British Journal of Cancer* 110, 242–248 | doi: 10.1038/bjc.2013.611
- Carpi M., Vincenzetti S., Pietro F., Napolioni V., Mignini F. 2011. Human DNA extraction methods: patents and applications. *Recent Patents on DNA & Gene Sequences* 5, 1-7
- Capper D., Weissert S., Balss J., Habel A., Meyer J., Jager D., Ackermann U., Tessmer C., Korshunov A., Zentgraf H., Hartmann C., Deimling V. 2010. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathol*; 20, 245-54.
- Ceccarelli M., Barthel F.P., Malta T.M., Sabedot T.S., Salama S.R., Murray B.A. 2016. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell*; 164: 550–563.
- Chesnelong C. 2015. *Isocitrate Dehydrogenase (IDH) Mutation in Glioma*. <https://www.researchgate.net/publication/275649572>. Chapter January 2015
- Clarke CRA. 2005. Neurological diseases in Kumar & Clark Clinical Medicine. Kumar P and Clark M. 6th ed. *Elsevier Saunders, Edinburgh*, pp 1244-45.
- Clarke J., Butowski N., Susan C. 2010. Recent Advances in Therapy for Glioblastoma. The JAMA Network. *Arch Neurol*;67(3):279-283
- Cohen A. L., Colman., 2015. Glioma biology and molecular markers, *Cancer Treat Res*, 163: 15-30.
- Combs S., Rieken S., Wick W., Abdollahi A., Deimling A., Debus J., Debus J., Hartmann C. 2011. Prognostic Significance of IDH-1 dan MGMT in Patients with Glioblastoma: One Step Forward, and One Step Back. *Radiat Oncol*; 6: 115.
- Campisi J. 2013. Aging, cellular senescence, and cancer. *Annu Rev Physiol*; 75:685–705. [PubMed: 23140366]
- Cardinale A., Nastrucci C., Cesario A., Russo P. 2012. Nicotine: specific role in angiogenesis, proliferation and apoptosis. *Crit Rev Toxicol*) 42:68–89.10.3109/10408444.2011.623150
- Cykowski M., Allen R., Fung K., Harmon M., Dunn S., 2012. Pyrosequencing of IDH1 and IDH2 Mutations in Brain Tumors and Non-Neoplastic Conditions. *Diagn Mol Pathol*; 21, 214-20.
- Dang L., White D., Gross S., Bennett B., Bittinger M., Driggers E., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M Ward P., Yen K. E., Liau L.M., Rabinowitz J., Cantley L.C., Thompson C.B. 2010. Cancer Associated IDH1 Mutations Produce 2 Hydroxyglutarate. *Nature*; 465, 966.
- Das B., Tangri R., Ahmad F., Roy A., Patole K. 2013. Molecular Investigation of Isocitrate Dehydrogenase Gene (IDH) Mutations in Gliomas: First Report of IDH2 Mutations in Indian Patients. *Asian Pac J Cancer Prev*; 14, 7261-4.



- Deeks SG. 2011. HIV infection, inflammation, immunosenescence, and aging. *Annu Rev Med*; 62(1):141–55. [PubMed: 21090961]
- Deitrich R., Zimatkin S., Pronko S. 2006. Oxidation of ethanol in the brain and its consequences. *Alcohol Res Health* ;29:266–73.
- Egan., Thompson R., Nabors L., Olson J., Brat D., Larocca R., Brem S., Moots P., Madden M., Browning J., Ann Chen Y. 2011. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. *J Neurooncol* 104(2): 535–542
- Ehrlichman., Ford J., Roelofs KJ., Tedeschi-Filho W., Futchko J., Ramacciotti E., Eliason J., Henke P. 2010. Upchurch GR Jr: Gender-dependent differential phosphorylation in the ERK signaling pathway is associated with increased MMP2 activity in rat aortic smooth muscle cells. *J Surg Res* 160:18-24.
- Evans MD., Dizdaroglu M., Cooke MS. 2004. Oxidative DNA damage and disease: induction, repair and significance. *Mutat Res* ;567:1–61.
- Felsberg J., Wolter M., Seul H., Friedensdorf B., Goppert M., Sabel M., Reifenberger G. 2010. Rapid dan Sensitive Assessment of The IDH1 dan IDH2 Mutation Status in Cerebral Gliomas Based on DNA Pyrosequencing. *Acta Neuropathol*; 119, 501-7.
- Fu Y., Huang R., Du J., Yang R., An N., Liang A. 2010. Glioma Derived Mutations in IDH: from Mechanism to Potential Therapy. *Biochem Biophys Res Commun*; 397, 127-30.
- Gardner., Larman M., Thouas G. 2010. Sex-related physiology of the preimplantation embryo. *Mol Hum Reprod* 16:539-547.
- Gravendeel L., Kloosterhof N., Bralten I., Marion V., Dubbink H., Dinjens W., Bleeker F., Hoogenraad C., Michiels E., Kros J., Smitt P., French P. 2010. Segregation of Non-p.R132H Mutations in IDH1 in Distinct Molecular Subtypes of Glioma. *Hum Mutant*; 31, E1186-99.
- Gresack., Schafe G., Orr PT., Frick K. 2009. Sex differences in contextual fear conditioning are associated with differential ventral hippocampal extracellular signal-regulated kinase activation. *Neuroscience* 159:451-467.
- Hakim, A. 2005. Tindakan Bedah pada Tumor Cerebellopontine Angle, *Majalah Kedokteran Nusantara* vol. 38. Hlm 3.
- Hanif F., Muzaffar K., Perveen K., Malhi S., Simjee S. 2017. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. *Asian Pac J Cancer Prev*;18 (1), 3-9



- Halpenny C., Yeh J., Lien W. 2015. Eldery Patient with Glioblastoma Multiform Treated with Concurrent Temozolamide and Standard versus Abbreviated-Course Radiotherapy. *The Permanente Journal*; 19(1):15-20.
- Hardiany N., Sadikin M., Wandani S. 2013. Ekspresi Relatif mRNA *Hypoxia Inducible Factor-1α* pada Sel Glioma Penderita. *Indonesian Journal of Cancer* 7.
- Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Untenberg A., Jeuken J., Wesseling P., Reifenberger G., Von D. 2009. Type and Frequency of IDH1 dan IDH2 Mutations Are Related to Astrocytic and Oligodendroglial Differentiation and Age: A Study of 1,010 Diffuse Gliomas. *Acta Neuropathol*; 118, 469-74.
- Heeschen C., Weis M., Aicher A., Dimmeler S., Cooke JP. 2002. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. *J Clin Invest* 110:527–36.10.1172/JCI0214676
- Hegi M., Diserens T., Gorlia M., Hamou N., de Tribolet M., Weller J., Kros., Hainfellner W., Mason L., Mariani J., Bromberg, P., Hau R., Mirimanoff J. G., Cairncross R. C., Janzer., Stupp. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma, *N Engl J Med*, 352: 997-1003.
- Hipolito L., Sanchez M., Polache A., Granero L. 2007. Brain metabolism of ethanol and alcoholism: an update. *Curr Drug Metab* ;8:716–27.
- Holick C., Giovannuci E., Rosner B., Stampher M., Michaud D. 2007. Prospective study of cigarette smoking and adult glioma: Dosage, duration, and latency. *Neuro Oncol*. Jul; 9(3):326-334
- Houillier C., Wang X., Kaloshi G. 2010. IDH1 or IDH2 Mutations Predict Longer Survival and Response to Temozolomide in Low Grade Gliomas. *Neurology*; 75(17):1560–1566.
- Hofer S., Rushing E., Preusser M., Marosi C. 2014. Molecular Biology of High Grade Gliomas: What Should the Clinician Know? *Chin. J. Cancer*; 33: 4–7.
- Hong-xing H., Xiao P., Qiang Z., Kai Z., Ming W., Yi-zhe L., Guang-liang H. 2016. Cigarette smoking and risk of adult glioma: a meta-analysis of 24 observational studies involving more than 2.3 million individuals. *Onco Target and Therapy*; 9 3511–3523.
- Horbinski C., Kofler J., Kelly L., Murdoch G., Nikiforova M. 2009. Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin Fixed, Paraffin Embedded Glioma Tissues. *J Neuropathol Exp Neurol*; 68, 1319-25.
- Howard C., Ken A. 2011. Current Clinical Oncology Chapter 2, 27-44. USA: Departement of Pathology University of Texas
- Howlander N., Noone A., Krapcho M. 2012. Cancer statistics review, 1975–2009 (Vintage 2009 Populations). *Bethesda MD*: National Cancer Institute



- Ichimura, K. 2012. Molecular Pathogenesis of IDH Mutations in Gliomas. *Brain Tumor Pathol*; 29, 131-9.
- Jenkins., Wrensch M., Johnson D., Fridley B., Decker P., Xiao Y., Kollmeyer TM., Rynearson A., Fink S., Rice T., McCoy L., Halder C., Kosel M., Giannini C., Tihan T., O'Neill B., Lachance D., Yang P., Wiemels J., Wiencke J. 2011. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. *Cancer genetics*. 204:13–8. [PubMed: 21356187]
- Jessen K., Mirsky R. 1980. Glial Cells in The Enteric Nervous System Contain Glial Fibrillary Acidic Protein. *Nature*, 286, 736-7.
- Jha P., Suri V., Sharma V., Singh G., Sharma M., Pathak P., Chosdol K. 2011. IDH1 Mutations in Gliomas: First Series from A Tertiary Care Centre in India with Comprehensive Review of Literature. *Exp Mol Pathol*; 91, 385-93.
- Johannesen A. 2006. The Clinical Value of Ki-67/MIB-1 Labeling Index in Human Astrocytomas. *Pathol Oncol Res*; 12 (3) : 143 - 7. DOI:PAOR.2006.12.3.0143
- Killela P.J., Pirozzi C.J., Reitman Z.J. 2013. The Genetic Landscape of Anaplastic Astrocytoma. *Oncotarget*; 5(6):1452–1457.
- Killela P., Reitman Z., Jiao Y. 2013. TERT Promoter Mutations Occur Frequently in Gliomas and Subset of Tumors Derived From Cells with Low Rates of Self-Renewal. *Proc Natl Acad Sci USA*;110(15):6021–6026.
- Kloosterhof N., Bralten L., Dubbink H., French P., Van den Bent M. 2011. Isocitrate Dehydrogenase-1 Mutations: A Fundamentally New Understanding of Diffuse Glioma? *Lancet Oncol*; 12, 83-91.
- Kobayashi., Isotani A., Mise N., Yamamoto M., Fujihara Y., Kaseda K., Nakanishi T., Ikawa M., Hamada H., Abe K., Okabe M. 2006. Comparison of gene expression in male and female mouse blastocysts revealed imprinting of the X-linked gene, RhoX5/Pem, at preimplantation stages. *Curr Biol* 16:166-172.
- Krell D., Assoku M., Galrendahay M., Mulholldan P., Tomlinson I., Bardella C. 2011. Screen for IDH1, IDH2, IDH3, D2HGDH dan L2HGDH Mutations in Glioblastoma. *PLoS One*; 6, e19868.
- Labussiere M., Boisselier K., Mokhtari A. L., Di Stefano A., Rahimian M., Rossetto P., Ciccarino O., Saulnier R., Paterra Y., Marie G., Finocchiaro., Sanson. 2014. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes, *Neurology*, 83: 1200-6.
- Lachance D., Yang P., Johnson D., Decker P., Kollmeyer T., McCoy L., Rice T., Xiao Y., Ali-Osman F., Wang F., Stoddard F., Sprau D., Kosel M., Wiencke J., Wiemels J., Patoka J., Davis F., McCarthy B., Rynearson A., Worra J., Fridley B., O'Neill B., Buckner J., Il'yasova D,



- Jenkins R., Wrensch M. 2011. Associations of High-Grade Glioma With Glioma Risk Alleles and Histories of Allergy and Smoking. *American Journal Epidemiology*. Vol. 174, No. 5 DOI: 10.1093/aje/kwr124
- Larjavaara., Mäntylä R., Salminen T., Haapasalo H., Raitanen J., Jääskeläinen J., Auvinen A. 2007. Incidence of gliomas by anatomic location. URL <http://neuro-oncology.dukejournals.org> DOI: 10.1215/15228517-2007-016
- Lee J., Cooke J. 2012. Nicotine and pathological angiogenesis. *Life Sci* 91:1058–64.10.1016/j.lfs.2012.06.032
- Lee J., Kim S., Kil I., Park J. 2007. Regulation of Ionizing Radiation-Induced Apoptosis by Mitochondrial NADP⁺ Dependent Isocitrate Dehydrogenase. *Journal Biology Chemistry*; 282, 13385-94.
- Lin J., Yao D., Qian J., Chen Q., Qian W., Li Y., Yang J., Wang C., Chai H., Qian Z., Xiao G., Xu W. 2012. IDH1 dan IDH2 Mutation Analysis in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Ann Hematology*; 91, 519-25.
- Louis D., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P., Jouvet A., Scheithauer B., Kleihues P. 2007. The 2007 WHO Classification of Tumours of The Central Nervous System. *Acta Neuropathology*; 114, 97-109.
- Louis D.N., Perry A., Reifenberger G., Von Deimling A., Figarella-Branger D., Cavenee W.K. 2016. The 2016 World Health Organization Classification of Tumors of The Central Nervous System: A Summary. *Acta Neuropathol. (Berl.)*; 131: 803–820.
- Matthew., Warkus., Displ., Yan H., 2015. Isocitrate Dehydrogenase Mutations in Gliomas. *Neuro-Oncology* ed July; 1–11
- McCarthy ., Auger A., Bale T., De Vries G., Dunn G., Forger N., Murray E., Nugent B., Schwarz J., Wilson ME.: 2009. The epigenetics of sex differences in the brain. *J Neurosci* 29:12815-12823.
- Metellus P., Coulibaly B., Colin C., De Paula A., Vasiljevic A., Taieb D., Barlier A., Boisselier B., Mokhtari K., Wang X., Loundou A., Chapon F., Pineau S., Ouafik L., Chinot O., Figarella B. 2010. Absence of IDH Mutation Identifies a Novel Radiologic dan Molecular Subtype of WHO Grade II Gliomas with Dismal Prognosis. *Acta Neuropathol*; 120, 719-29.
- Morokoff A., Ng W., Gogos A., Kaye A.H. 2015. Molecular Subtypes, Stem Cells and Heterogeneity: Implications for Personalised Therapy in Glioma. *J. Clin. Neurosci*; 22: 1219–1226.
- Mousa S., Mousa S. 2006. Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. *J Cell Biochem* 97:1370–8.10.1002/jcb.20741



- Mukasa A., Takayanagi S., Saito K., Shibahara J., Tabei Y., Furuya K., Ide T., Narita Y., Nishikawa R., Ueki K., Saito N. 2012. Significance of IDH Mutations Varies with Tumor Histology Grade and Genetics in Japanese Glioma Patients. *Cancer Science*; 103, 587-92.
- Myung J., Cho H., Park C., Kim S., Phi J., Park S. 2012. IDH1 Mutation of Gliomas with Long Term Survival Analysis. *Oncology Reports Volume 28 Issue 5 Pages:1639-1644*
- Nelson D.E., Jarman D.W, Rehm J. 2013. Alcohol attributable cancer deaths and years of potential life lost in the US. *J Public Health*; 103(4):641–8.
- Ohno M., Narita Y., Miyakita Y., Matsushita Y., Yoshida A., Fukushima S., Ichimura K., Shibui S. 2013. Secondary Glioblastomas with IDH1/2 Mutations Have Longer Glioma History from Preceding Low Grade Gliomas. *Brain Tumor Pathol*; 30, 224-32.
- Ohno M., Narita Y., Miyakita Y., Okita Y., Matshushita Y., Yoshida A., Fukushima S., Ichimura K., Kayama T., Shibui S. 2012. Histopathological Malignant Progression of Grade II and III Gliomas Correlated with IDH1/2 Mutation Status. *Brain Tumor Pathol*; 29, 183-91.
- Ordys., Launay S., Deighton R., McCulloch J., Whittle I. 2010. The role of mitochondria in glioma pathophysiology. *Mol Neurobiol* 42:64-75.
- Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. 1982. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. *Am J Clin Oncol*; 5:649-655.
- Omuro A, DeAngelis LM. 2013. Glioblastoma and other malignant gliomas: a clinical review. *J Am Med Assoc*; 310, 1842–50.
- Oslobanu., Florian. 2015. Anatomic locations in high grade glioma. *Romanian Neurosurgery*; XXIX 3: 256 - 262
- Ostrom Q.T., Gittleman H., Farah P., Ondracek A., Chen Y., Wolinsky Y. 2013. Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in The United States in 2006–2010. *Neuro-oncol*; 15(Suppl 2):ii1–ii56.
- Oyesanmi O., Snyder D., Sullivan N. 2010. Alcohol consumption and cancer risk: understanding possible causal mechanisms for breast and colorectal cancers. Rockville MD: Agency for Healthcare Research and Quality; Nov. Evidence Report/Technology Assessment No. 197 (prepared by ECRI Institute Evidence-based Practice Center under Contract No. 290-2007-10063-I). AHRQ Publication No. 11-E003
- Padmosantjojo R. 2003. *Brain Tumors in Indonesia. Proceedings of the 17th Asia Pasific Cancer Congress. Bal. Indonesia.*
- Parson D., Jones S., Zhang X., Lin J., Learly R., Angenendt P., Mankoo P., Carter H., Siu I., Galla G., Olivi A., Mclendon R., Rasheed B., Keir S., Nikolskaya T., Nikolsky Y., Busam D.,



- Tekleab H., Diaz L., Hartigan J., Smith. 2008. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. *Science*; 321, 1807-12.
- Pessoa A., Sagica F., Anselmo N., Brito J., Oliveira E. 2014. IDH 1 and IDH 2 mutations in different histologic subtypes and WHO grading glioma in a sample from Northern Brazil. *Genetics and Molecular Research online Journal*; Genet. Mol. Res. 14 (2): 6533-6542
- Pignataro L., Miller A., Ma L., Midha S., Protiva P., Herrera DG., Harrison NL. 2007. Alcohol regulates gene expression in neurons via activation of heat shock factor 1. *J Neurosci* 27: 12957-66.
- Posti J.P, Bori M., Kauko T., Sankinen M., Nordberg J., Rahi M., Frantz en J., Vuorinen V. 2015. Presenting symptoms of glioma in adults. *Acta Neurol Scand*; 131: 88 – 93.2014
- Qiagen. 2012. QIAamp DNA FFPE Tissue Handbook For purification of genomic DNA from formalin-fixed paraffin-embedded tissues. www.qiagen.com.
- Qi Yu-Zhen., Shao C., Yang C., Wang Z., Hui Z. 2014. Alcohol Consumption and Risk of Glioma: A Meta-Analysis of 19 Observational Studies. *Nutrients*;6, 504-516.
- Raynaud S., Carbuccia N., Colin C., Adelaide J., Mozziconacci M., Metellus P., Chinot O., Birbaum D., Chaffanet M., Figarella D. 2010. Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas dan breast cancers. *Oncol Lett*; 1, 883-884.
- Retman Z., Yan H. 2010. Isocitrate dehydrogenase 1 dan 2 mutations in cancer: alterations at a crossroads of cellular metabolism. *J Natl Cancer Inst*; 102, 932-41.
- Ruda R., Pellerino A., Magistrello M., Franchino F., Pinessi L. Soffiatti R. 2015. Molecularly based management of gliomas in clinical practice. *Neurol. Sci.*; 36: 1551-1557.
- Sanchez F., Vilain. 2010. Genes and brain sex differences. *Prog Brain Res*186:65-76.
- Sanner T., Grimsrud. 2015. Nicotine: Carcinogenicity and Effects on Response to Cancer Treatment – A Review. *Front Oncol*. 2015; 5: 196. doi: 10.3389/fonc.2015.00196
- Seitz H., Stickel F. 2007. Molecular mechanisms of alcohol-mediated carcinogenesis. *Nat Rev Cancer* ;7:599-612.
- Sibara I., Sonoda Y., Kanamori M., Saito R., Kumabe T., Tominaga T. 2011. New insights into glioma classification based on isocitrate dehydrogenase 1 dan 2 gene status. *Brain Tumor Pathol*; 28, 203-8.
- Shaywitz., Greenberg. 1999. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. *Annu Rev Biochem* 1999, 68:821-861.
- Shibahara I., Sonoda Y., Kanamori M., Saito R., Yamashita Y., Kumabe T., Watanabe M., Suzuki H., Kato S., Ishioka C., Tominaga T. 2012. IDH1/2 gene status defines the prognosis dan molecular profiles in patients with derajat III gliomas. *Int J Clin Oncol*; 17, 551-61.



- Simon., Hosking F., Marie Y., Gousias K., Boisselier B., Carpentier C., Schramm J., Mokhtari K., mHoang-Xuan K., Idbaih A., Delattre J., Lathrop M., Robertson L., Houlston R., Sanson M. 2011. Genetic risk profiles identify different molecular etiologies for glioma. *Clin Cancer Res.* 16:5252–9. [PubMed: 20847058]
- SongTao Q., Lei G., Si D., YanQing, H., HuiXia Z., XueLin W., LanXiao., Fei. 2012. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. *Cancer Sci*, 103: 269-73.
- Sonoda Y., Kanamori M., Saito R., Yamashita Y., Kumabe T., Watanabe M., Suzuki H., Kato S., Ishioka C., Tominaga T. 2009. Analysis of IDH1 dan IDH2 mutations in Japanese glioma patients. *Cancer Sci*; 100, 1996-8.
- Suzuki H., Aoki K., Chiba K. 2015. Mutational Landscape and Clonal architecture in grade II and III gliomas. *Nat Genet*; 0:1–14.
- Uno M., Oba S., Silva R., Miura F., Clara C., Almeida J., Malheiros S., Bianco A., Brdant R., Ribas G., Feres H., Dzik C., Rosemberg S., Stavale J., Teixeira M., Marie S. 2011. IDH1 mutations in a Brazilian series of Glioblastoma. *Clinics (Sao Paulo)*; 66, 163-5.
- Van den Bent M., Dubbink H., Marie Y., Brdanes A., Taphoorn M., Wesseling P., Frenay M., Tijssen C., Lacombe D., Idbaih A., Van-Marion R., Kros J., Dinjen W., Gorlia T., Sanson. 2010. IDH1 dan IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research dan Treatment of Cancer Brain Tumor Group. *Clin Cancer Res*; 16, 1597-604.
- Wagner S., Benesch M., Berthold F., Gnekow A., Rutkowski S., Starter R., Warmuth M., Kortmann R., Pietsch T., Wolff A. 2006. Secondary Dissemination in Children With High-Grade Malignant Gliomas and Diffuse Intrinsic Pontine Gliomas. *British Journal of Cancer*; Oct 23;95(8);991-997
- Waitkus M., Diplas B., Yan H. 2015. Isocytat Dehydrogenase Mutations in Gliomas. *Neuro-Oncology Advance Access July 16, 2015*
- Wang, H., Xu Y., Jiang H., Xu Y., Yan D., Fu., Chen. 2015. The challenges and the promise of molecular targeted therapy in malignant gliomas. *Neoplasia*, 17: 239-55.
- Whittle I. 2004. Dilemma Of Low Grade Glioma. *J neurol Neurosurg Psychiatry*; 75(Suppl III); ii31-ii36. Doi:10.1136/jnnp.2004.040501
- Wick W., Hartmann C., Engel C., Stoffels M., Felsberg J., Stockhammer F., Sabel M., Koeppen S., Ketter R., Meyermann R., Rapp M., Meisner C., Kortmann R., Pietsch T., Wiestler O., Ernemann U., Bamberg M., Reifenberger G., Von Deimling A., Weller M. 2009. NOA-04 Randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, dan vincristine or temozolomide. *J Clin Oncol*;27, 5874-80.



- Wilson C., Davies D. 2007. The control of sexual differentiation of the reproductive system and brain. *Reproduction* 133:331-359.
- Yan H., Parsons D., Jin G., McLendon R., Rasheed B., Yuan W., Kos I., Batinic I., Jones S., Riggins G., Friedman H., Reardon D., Herdon J., Konzler K., Velculescu V., Vogelstein B., Bigner D. 2009. IDH1 dan IDH2 mutations in gliomas. *N Engl J Med*, 360, 765-73.
- Yan H., Parsons D., Jin G. 2009. IDH1 dan IDH2 mutations in gliomas.. *N Engl J Med*; 360 (8) : 765–773.
- Zhang W., Chen L., Jiang T. 2014. Correlation of IDH1/2 mutation with clinicopathologic factors dan prognosis in anaplastic gliomas: a report of 203 patients from China. *J Cancer Res Clin Oncol*; 140, 45-51.
- Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong, L., Peng Y., Ding J., Lei Q., Guan K., Xiong Y. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity dan induce HIF-1alpha. *Science*; 324, 261-5.
- Zhu J., Zou J., Xu Q., Wang X., Wang Z., Zhou., D. 2011. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. *Med Hypotheses*; 76, 602-3.
- Zorzan M., Giordan E., Redaelli M., Caretta A., Mucignat-Caretta C. 2015. Molecular targets in glioblastoma. *Future Oncol*; 11: 1407–1420.
- Raynaud S., Carbuccia N., Colin C., Adélaïde J., Mozziconacci M.-J., Metellus P. 2010. Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas dan breast cancers. *Oncol. Lett*; 1: 883–884.
- Van den Bent M.J., Dubbink H.J., Marie Y., Brdanes A.A., Taphoorn M.J.B., Wesseling P. 2010. IDH1 dan IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research dan Treatment of Cancer Brain Tumor Group. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 16: 1597–1604.